Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART

about

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART

Item

http://www.wikidata.org/entity/Q58585537

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Randomized Clinical Trial to A ...... n Individuals on Effective ART

@en

Randomized Clinical Trial to A ...... n Individuals on Effective ART

@nl

type

Item

label

Randomized Clinical Trial to A ...... n Individuals on Effective ART

@en

Randomized Clinical Trial to A ...... n Individuals on Effective ART

@nl

prefLabel

Randomized Clinical Trial to A ...... n Individuals on Effective ART

@en

Randomized Clinical Trial to A ...... n Individuals on Effective ART

@nl

P1476

Randomized Clinical Trial to A ...... n Individuals on Effective ART

@en

P2093

Bernard J C Macatangay

http://www.w3.org/2001/XMLSchema#string

Christine M Durand

http://www.w3.org/2001/XMLSchema#string

John W Mellors

http://www.w3.org/2001/XMLSchema#string

Joshua C Cyktor

http://www.w3.org/2001/XMLSchema#string

Justin Ritz

http://www.w3.org/2001/XMLSchema#string

Lu Zheng

http://www.w3.org/2001/XMLSchema#string

Michael C Keefer

http://www.w3.org/2001/XMLSchema#string

Richard A Koup

http://www.w3.org/2001/XMLSchema#string

Robert T Bailer

http://www.w3.org/2001/XMLSchema#string

Sharon A Riddler

http://www.w3.org/2001/XMLSchema#string

P2860

Latent reservoirs of HIV: obstacles to the eradication of virus

Elimination of HIV-1-infected cells by broadly neutralizing antibodies

Broadly Neutralizing Antibodies for HIV Eradication

Broad neutralization coverage of HIV by multiple highly potent antibodies

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.

P304

ofy242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/OFID/OFY242

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Julie Ledgerwood

Joseph J Eron

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30364428

http://www.w3.org/2001/XMLSchema#string

P932

6195652

http://www.w3.org/2001/XMLSchema#string